Nav: Home

New drug may protect against memory loss in Alzheimer's disease

September 09, 2019

BUFFALO, N.Y. ¬- A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss, nerve damage and other symptoms of Alzheimer's disease.

Preclinical research found that the drug -- called BPN14770 -- deters the effects of amyloid beta, a hallmark protein of Alzheimer's that is toxic to nerve cells.

Recent studies find Alzheimer's may develop without dementia in nearly 25% of healthy 80-year-old patients, suggesting the body may turn to compensatory mechanisms to maintain the nervous system.

BPN14770, under development by Tetra Therapeutics, could help activate these mechanisms that support nerve health and prevent dementia, even with the progression of Alzheimer's.

Its benefits could also translate to Fragile X syndrome, developmental disabilities and schizophrenia, researchers say.

"Such observations imply that Alzheimer's pathology can be tolerated by the brain to some extent due to compensatory mechanisms operating at the cellular and synaptic levels," said Ying Xu, MD, PhD, co-lead investigator and research associate professor in the UB School of Pharmacy and Pharmaceutical Sciences.

"Our new research suggests that BPN14770 may be capable of activating multiple biological mechanisms that protect the brain from memory deficits, neuronal damage and biochemical impairments."

The study, published on Sept. 5 in the Journal of Pharmacology and Experimental Therapeutics, was also led by James M. O'Donnell, PhD, dean and professor of the UB School of Pharmacy and Pharmaceutical Sciences. Mark E. Gurney, PhD, chairman and chief executive officer of Tetra Therapeutics, based in Grand Rapids, Michigan, collaborated on the research.

Guarding memory against toxic proteins

The research, conducted in mice, discovered that BPN14770 inhibits the activity of phosphodiesterase?4D (PDE4D), an enzyme that plays a key role in memory formation, learning, neuroinflammation and traumatic brain injury.

PDE4D lowers cyclic adenosine monophosphate (cAMP) -- a messenger molecule that signals physiological changes such as cell division, change, migration and death -- in the body, leading to physical alterations in the brain.

cAMP has numerous beneficial functions, including improved memory. By inhibiting PDE4D, BPN14770 increases cAMP signaling in the brain, which ultimately protects against the toxic effects of amyloid beta.

"The role of PDE4D in modulating brain pathways involved in memory formation and cognition, and the ability of our PDE4D inhibitor to selectively enhance this process, has been well studied," said Gurney. "We are very excited by our colleagues' findings, which now suggest a second protective mechanism of action for BPN14770 against the progressive neurological damage associated with Alzheimer's disease."

"Developing effective drugs for memory deficits associated with Alzheimer's disease has been challenging," said O'Donnell. "BPN14770 works by a novel mechanism to increase cyclic AMP signaling in the brain, which has been shown to improve memory. The collaborative project has led to clinical trials that will begin to test its effectiveness."

Tetra Therapeutics is conducting Phase 2 clinical trials of BPN14770 in patients with early Alzheimer's and adults with Fragile X syndrome, a genetic disorder that causes intellectual and developmental disabilities.

Results of previous Phase 1 studies in healthy elderly volunteers suggest the drug benefits working, or immediate, memory. Animal studies found that BPN14770 has the potential to promote the maturation of connections between neurons, which are impaired in patients with Fragile X syndrome, as well as protect these connections, which are lost in patients with Alzheimer's.

"There has been enormous interest in our ongoing Phase 2 trial of BPN14770 in 255 patients with early Alzheimer's, and we are hopeful this study will show an impact of PDE4D modulation in this disease. Topline results are expected mid-2020," said Gurney.
-end-
The research was supported by the National Institutes of Health Blueprint Neurotherapeutics Network through the National Institute of Neurological Disorders and Stroke, National Institute on Aging and National Institute of Mental Health.

About Tetra Therapeutics

Tetra Therapeutics is a clinical stage biotechnology company developing therapeutic products for Alzheimer's disease, Fragile X syndrome, traumatic brain injury and other brain disorders.

For more information, please visit the company's website.

University at Buffalo

Related Memory Articles:

How long does memory last? For shape memory alloys, the longer the better
Scientists captured live action details of the phase transitions of shape memory alloys, giving them a better idea how to improve their properties for applications.
Seeing it both ways: Visual perspective in memory
Think of a memory from your childhood. Are you seeing the memory through your own eyes, or can you see yourself, while viewing that child as if you were an observer?
A NEAT discovery about memory
UAB researchers say over expression of NEAT1, an noncoding RNA, appears to diminish the ability of older brains to form memories.
Molecular memory can be used to increase the memory capacity of hard disks
Researchers at the University of Jyväskylä have taken part in an international British-Finnish-Chinese collaboration where the first molecule capable of remembering the direction of a magnetic above liquid nitrogen temperatures has been prepared and characterized.
Memory transferred between snails
Memories can be transferred between organisms by extracting ribonucleic acid (RNA) from a trained animal and injecting it into an untrained animal, as demonstrated in a study of sea snails published in eNeuro.
An immunological memory in the brain
Inflammatory reactions can change the brain's immune cells in the long term -- meaning that these cells have an 'immunological memory.' This memory may influence the progression of neurological disorders that occur later in life, and is therefore a previously unknown factor that could influence the severity of these diseases.
Anxiety can help your memory
Anxiety can help people to remember things, a study from the University of Waterloo has found.
Pores with a memory
Whether for separation processes, photovoltaics, catalysis, or electronics, porous polymer membranes are needed in many fields.
Memory gene goes viral
Two independent teams of scientists from the University of Utah and the University of Massachusetts Medical School have discovered that a gene crucial for learning, called Arc, can send its genetic material from one neuron to another by employing a strategy commonly used by viruses.
Neurobiology: The chemistry of memory
Learning requires the chemical adaptation of individual synapses. Researchers have now revealed the impact of an RNA-binding protein that is intimately involved in this process on learning and memory formation and learning processes.
More Memory News and Memory Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.